ClinicalTrials.gg
CompletedNCT01518101PREFERUpdated Feb 27, 2017

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications

A Phase 4 interventional study of Vildagliptin/ Metformin and Liraglutide in Type 2 Diabetes, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Germany. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
79th of 118
62 · median 162
Started
2012
with 9 others
Phase 4
43 of 119
none open now
Registered
80th of 119
by date
Lead sponsor
47 of 119
Novartis Pharmaceuticals

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 79th largest by enrollment of the 118 interventional ones that give a count, is one of 10 that started in 2012, is one of 43 in phase 4, and was the 80th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or analogs, which rely on the gastrointestinal hormones that are part of the incretin system for the treatment of T2DM, provide a therapeutic alternative to common oral antihyperglycemic agents (eg, sulfonylureas, thiazolidinediones). Although GLP-1 analogs and DPP-4 inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). Previous studies have shown that patients prefer additional oral agents over injectable agents because of fear of injections and the desire to avoid them. Patient preference is both clinically and financially important, as it can have long-term implications in terms of patients' motivation and insight into their disease state and its treatment, which might have a direct impact on the patient's compliance and treatment adherence. The aim of the current study is to evaluate the proportion of T2DM patients preferring oral anti-diabetic treatment with vildagliptin + metformin versus an injectable anti-diabetic treatment with liraglutide after 4 weeks of treatment with each medication.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • patient preference
  • vildagliptin
  • liraglutide
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes
  • Metformin monotherapy > 12 weeks
  • (HbA1c) > 6.5 % and \< 9.0 %
  • (BMI) 19-35 (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • acute diseases at randomization
  • kidney diseases with creatinin > 120 µmol/l, (GFR) \<50 ml/min
  • for Gliptins or glucagon-like-peptide-analogues according to the respective Summary of Product Characteristics (SmPC)
  • previous use of dipeptidyl peptidase-4-inhibitors and GLP-1-mimetics

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Vildagliptin/Metformin followed by Liraglutide+Metformin

    In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.

    Drug: Vildagliptin/ Metformin · Drug: Liraglutide · Drug: Metformin

  • Experimental
    Liraglutide + Metformin followed by Vildagliptin/Metformin

    In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.

    Drug: Vildagliptin/ Metformin · Drug: Liraglutide · Drug: Metformin

Interventions

  • DrugVildagliptin/ Metformin

    Drug pages: Vildagliptin · Metformin

    Single pill combination of Vildagliptin/ Metformin (50/1000 mg).

  • 1.2 mg once daily by commercially available injection pens

  • 1000 mg tablets twice daily

06

What researchers measure

Primary outcomes

  1. Proportion of patients preferring each treatment regimen

    Individual patient preference will be assessed by a two-choice question.

    Time frame: At week 24

Secondary outcomes

  1. Number of patients with treatment satisfaction for each treatment measured by Diabetes Treatment Satisfaction Questionnaire (TSQM-9)

    The TSQM -9 is a psychometrically measure of the major dimensions of patients' satisfaction with medication. It provides scores on 3 scales: effectiveness (3 items), convenience (3 items) and global satisfaction (3 items).

    Time frame: week 12, Week 24

  2. Number of patients responding to subjective reasons of preference to each treatment

    Individual patient preference will be assessed by a two-choice question. Patients will also be asked to specify the reason for preference. A specific questionnaire for the preference reasons will be provided.

    Time frame: Week 12, week 24

  3. Number of patients with adverse event, serious adverse events and death

    Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

    Time frame: 24 weeks

  4. Change from baseline in fasting plasma glucose at 12 weeks and 24 weeks

    Blood glucose measurements will be performed at baseline, week 12 and week 24 visits.

    Time frame: From Baseline to 12 weeks and 24 weeks

  5. Change From Baseline in Hemoglobin A1c (HbA1c) at week 12 and week 24

    HbA1c measurements will be performed at baseline, week 12 and week 24 visits.

    Time frame: From Baseline to 12 weeks and 24 weeks

  6. Investigator preference and subjective reasons of preference to each treatment

    Investigator preference will be assessed by a two-choice question. Investigator will also be asked to specify the reason for preference. A specific questionnaire for the preference reasons will be provided.

    Time frame: Week 12, week 24

07

Study locations

8 sites
  • Novartis Investigative Site
    Berlin, 10115, Germany
  • Novartis Investigative Site
    Berlin, 13055, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Falkensee, 14612, Germany
  • Novartis Investigative Site
    Meissen, 01662, Germany
  • Novartis Investigative Site
    Neunkirchen, 57290, Germany
  • Novartis Investigative Site
    Saarlouis, 66740, Germany
  • Novartis Investigative Site
    Völlkingen, 66333, Germany
08

References and documents

Publications

  • Ludemann J, Dutting ED, Dworak M. Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study. Ther Adv Endocrinol Metab. 2015 Aug;6(4):141-8. doi: 10.1177/2042018815595584. PubMed 26301063 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2012
First posted
Jan 25, 2012
Start
Jan 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01518101
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Jan 2012
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Feb 27, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Metformin · Liraglutide

Start the discussion